Jennifer Kim, PhD, assistant research professor, Tufts School of Medicine, Tufts Center for the Study of Drug Development, discusses barriers to participation for underrepresented populations in clinical trials and how Tufts is conducting research to better understand their nature.

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Pamela Tenaerts, chief scientific officer, Medable, discusses the need for more data around the implementation of clinical technology.

With an increased need for operational efficiency, while also leveraging new technologies such as AI, the landscape of clinical operations is evolving, as our February issue explores.

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Shakthi Kumar, chief strategy & business officer, Edetek, discusses how Edetek's R&D cloud system addresses challenges in clinical data management.

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.

The long-held practice is effective in pinpointing the emergence of known and unknown risks to clinical development, study shows.

Phase III EV-302/KEYNOTE-A39 trial confirms that the combination of Padcev (enfortumab vedotin) and Keytruda (pembrolizumab) provides sustained and significant overall survival and progression-free survival benefits compared to chemotherapy in previously untreated patients with locally advanced or metastatic urothelial cancer.

Progress made in measuring decentralized clinical trial use in patient recruitment and retention.

Examining those technology-supported areas that sponsors, CROs, and sites consider the most valuable.

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Jonathan Norman, director, localization services, YPrime, discusses the importance of communicating with patients in their native languages.

Leveraging and benchmarking insights to boost efficiency and optimization.

The key considerations for sponsors in deciding whether to claim the credit.

Insights identify opportunities to optimize sponsor, CRO, and site collaborations.

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Richard Young, chief strategy officer, Cluepoints, offers his key takeaways from this year's SCOPE Summit in Orlando.

Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, reinforcing its potential as an effective treatment option while also allowing for a reduction in corticosteroid use.

Engaging with ineligible participants can transform a potentially negative experience into a positive one.

The conundrum of missing data vs. inter-rater variability.

Tips and best practices for empowering professionals to become change agents in their institutions, including clinical trials.

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Peter Ronco, CEO, Emmes, provides advice to small biopharma companies looking to scale their clinical programs without overextending resources.

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Richard Young, chief strategy officer, CluePoints, discusses goals of the SCOPE Summit and CluePoints' evolving approach to risk detection.

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Patil, vice president, digital innovation, IQVIA, discusses how artificial intelligence/machine learning can help in areas such as feasibility, site selection, and patient recruitment.

In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.

Session explores innovation in operationalizing clinical trials and how challenges with adoption can be addressed.

In an interview with Applied Clinical Trials Associate Editor Don Tracy Peter Ronco, CEO, Emmes, discusses the number of risks small biopharma companies taken when taking on clinical trial partners/

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Garty, chief technology officer, clinical data, provided his key takeaways from a panel he participated in on the growing interest around pragmatic studies.